atogepant is FDA approved. Atogepant, marketed under the brand name Qulipta, received FDA approval on September 28, 2021.

YolTech Therapeutics has announced the successful enrollment of the inaugural patient in the Phase I clinical trial of YOLT-201.

Tisotumab vedotin (Tivdak) received accelerated approval from the US Food and Drug Administration (FDA) on September 20, 2021.

Olatec Therapeutics, Inc., a pioneer in the field of selective NLRP3 inhibitors, revealed that individuals with type 2 diabetes mellitus and associated diabetic complications are currently being recruited

Mobocertinib (Exkivity) received accelerated approval from the US Food and Drug Administration (FDA) on September 15, 2021.

If approved, crinecerfont will be the first new treatment option for CAH in 70 years and represents a novel therapeutic approach, offering a new treatment method for this rare and severe endocrine disorder.

Lonapegsomatropin (Skytrofa) received FDA approval on August 25, 2021.

Vivani Medical, Inc., a pioneering company in biopharmaceuticals, revealed plans to commence the inaugural clinical trial for the NPM-115 initiative in Australia.

The U.S. Food and Drug Administration (FDA) approved Difelikefalin on August 23, 2021, for the treatment of moderate-to-severe pruritus (itching) associated with chronic kidney disease in adults undergoing hemodialysis (HD).

Radioligand therapy (RLT), as a part of radiopharmaceuticals, delivers high-energy radiation directly to cancer cells by targeting their structural or biochemical mutations.

The U.S. Food and Drug Administration (FDA) approved Belzutifan on August 13, 2021, for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC).

Pfizer have chosen the preferred once-daily modified release form of danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist.